Current Neuro-Oncology
Volume
27 Number 11
20 April 2025
Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 11, 20 April
Shi X, Sun X, Fan W, Dai X, Jiang M.
Impact
of radiation response on survival in pediatric medulloblastoma
with residual or disseminated disease.
Radiat
Oncol. 2025 Apr 11;20(1):52. doi:
10.1186/s13014-025-02632-9. PMID:
40217253. Observational study. ˍ
Cao H, Huang Z, Qiu R, Xiao X, Li Z, Pillai JJ, Hua J, Huang G, Xu
Y, Liang W, Wu Y.
Predicting
progression of enhancing non-measurable disease in high-grade
glioma by using dynamic contrast-enhanced MR imaging. Magn
Reson Imaging. 2025 Apr 12:110394. doi:
10.1016/j.mri.2025.110394. PMID:
40222718. Observational study˰
ˍ
Li D, Chen Y, Wong TF, Yang Q, Guo C, Jiang X, Ke C, Zhang X, Zeng
J, Lv Y, Wu S, Wang J, Sai K, Mou Y, Chen Z.
Management
and survival trends for diffuse gliomas diagnosed at a single
neurooncology center in China during 2000 to 2020.
Sci
Rep. 2025 Apr 12;15(1):12574. doi:
10.1038/s41598-025-95693-5. PMID:
40221458. Observational study. ˍ
Diaz LS, Agrup M, Askild A, Embring A, Engellau J, Kristensen IF,
Flejmer A, Fröjd C, Nilsson MP, Svärd AM, Walfridsson A,
Blomstrand M.
Acute side effects of
proton and photon radiotherapy for medulloblastoma: a
retrospective national multicenter study.
J
Neurooncol. 2025 Apr 15. doi:
10.1007/s11060-025-05016-x. PMID:
40232619. Observational study. ˍ
Lesha E, Laird DG, Nichols CS, Miller LE, Orr T, Roach JT, Troy C,
Vaughn B, Shimony N, Klimo P Jr.
Variables
associated with 90-day readmission following craniotomy for tumor
in the pediatric population.
J
Neurooncol. 2025 Apr 15. doi:
10.1007/s11060-025-05021-0. PMID:
40232620. Observational study. ˍ
Chung MW, Tzeng CC, Huang YC, Wei KC, Hsu PW, Chuang CC, Lin YJ,
Chen KT, Lee CC.
Neutrophil-to-lymphocyte
ratio dynamics: prognostic value and potential for surveilling
glioblastoma recurrence.
BMC
Cancer. 2025 Apr 16;25(1):709. doi:
10.1186/s12885-025-14118-8. PMID:
40241016. Observational study. ˍ
Li Y, Shen X, Zhang J, Xian X, Chen S, Zeng J, Hu W.
Adult
diffuse IDH-wildtype lower-grade gliomas with PDGFRA
gain/amplification should be upgraded as glioblastoma.
J
Neuropathol Exp Neurol. 2025 Apr 16:nlaf039. doi:
10.1093/jnen/nlaf039. PMID:
40238212. Laboratory investigation˰
ˍ
Nakatogawa H, Fukai J, Kawaji H, Hayashi N, Yoshioka E, Kodama Y,
Nakajo K, Uda T, Arakawa Y, Takada S, Kijima N, Ishibashi K, Okuda
T, Sonoda Y, Ohue S, Arita H, Matsuda M, Fukami T, Tomita T, Inoue
A, Achiha T, Kashiwagi H, Kanematsu D, Katsuma A, Sumida M,
Shofuda T, Mano M, Kinoshita M, Mori K, Inenaga C, Kanemura Y.
Characteristics and outcomes of
diffuse non-midline gliomas with H3F3A gene mutation in the Kansai
Molecular Diagnosis Network for CNS Tumors (Kansai Network):
multicenter retrospective cohort study.
Acta
Neuropathol Commun. 2025 Apr 16;13(1):77. doi:
10.1186/s40478-025-01989-y. PMID:
40241149. Observational study. ˍ
Xu H, Jiang LH, Yu SN, Ren QL.
The
Prognostic Value of the Systemic Immune-Inflammation Index in
Glioblastoma Patients and the Establishment of a Nomogram.
Curr
Med Sci. 2025 Apr 16. doi:
10.1007/s11596-025-00047-x. PMID:
40240723. Observational study˰
ˍ
Fangusaro J, Onar-Thomas A, Young Poussaint T, Lensing S, Ligon
AH, Lindeman N, Banerjee A, Kilburn LB, Lenzen A, Pillay-Smiley N,
Pollack IF, Robison NJ, Partap S, Qaddoumi I, Landi D, Jones DTW,
Stewart CF, Fouladi M, Dunkel IJ.
A
Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive
Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term
Outcomes on Strata 1, 3, and 4.
Neuro
Oncol. 2025 Apr 17:noaf065. doi:
10.1093/neuonc/noaf065. PMID:
40241281. Interventional study˰
ˍ